Novel Agents for the Treatment of Primary Plasma-Cell Leukemia: Lights and Shadows

Publisher： Karger

E-ISSN： 1421-9662|135|2|110-112

ISSN： 0001-5792

Source： Acta Haematologica, Vol.135, Iss.2, 2016-0, pp. : 110-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma

By  

Acta Haematologica, Vol. 135, Iss. 2, 2016-0 ,pp. : 113-121

Karger

Access to resources Recommend Favorite

Combination therapy incorporating Bcl‐2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 2, 2018-02 ,pp. : 215-217

John Wiley & Sons Inc

Access to resources Recommend Favorite

Thalidomide Administration for the Treatment of Resistant Plasma Cell Leukemia

By  

Acta Haematologica, Vol. 109, Iss. 3, 2003-05 ,pp. : 153-155

Karger

Access to resources Recommend Favorite

Plasma‐Cell Mastitis: Case Report

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 22, Iss. 1, 1974-01 ,pp. : 39-42

John Wiley & Sons Inc

Access to resources Recommend Favorite

Significantly Better Prognosis for Patients with Primary Plasma Cell Leukemia than for Patients with Secondary Plasma Cell Leukemia

By  

Acta Haematologica, Vol. 118, Iss. 3, 2007-10 ,pp. : 178-182

Karger

Access to resources Recommend Favorite